(Q41612091)

5 October 2017

title

Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial (English)

1 reference

5 October 2017

A R Nissenson

1

1 reference

5 October 2017

R M Lindsay

2

1 reference

5 October 2017

S Swan

3

1 reference

5 October 2017

P Seligman

4

1 reference

5 October 2017

J Strobos

5

1 reference

5 October 2017

publication date

1 March 1999

1 reference

American Journal of Kidney Diseases

5 October 2017

published in

1 reference

5 October 2017

volume

33

1 reference

5 October 2017

issue

3

1 reference

5 October 2017

page(s)

471-482

1 reference

Characterization of the anemia associated with chronic renal insufficiency

5 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

A randomized controlled study of iron supplementation in patients treated with erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

Iron status in patients receiving erythropoietin for dialysis-associated anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

The safety of intravenous iron dextran in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

Intravenous Fe-gluconate-Na for iron-deficient patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

Iron balance in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

Intra-dialytic oral iron therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

Serum ferritin: does it differ from tissue ferritin?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970184-8

7 January 2021

10.1016/S0272-6386(99)70184-8

Identifiers

DOI

1 reference

5 October 2017

1 reference